# ADMA Biologics (ADMA) — Earnings

ADMA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/adma/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $0.16 |
| EPS estimate | $0.16 |
| EPS surprise | +0.98% |
| Revenue surprise | −0.76% |
| Revenue | $124.4M |
| Revenue estimate | $125.3M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1368514/000114036126031445/ef20075111_10q.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/06fc0bbd-93fc-fea4-a3a3-fdc775d26308.html) |

ADMA Biologics reported Q2 2026 results on August 5, 2026. EPS was $0.16, 0.98% above the $0.16 estimate. Revenue of $124.4 million was 0.76% short of the $125.3 million consensus. Against Q2 2025, EPS rose 6.7% from $0.15 and revenue rose 2.0% from $122.0 million.

The table shows a move from losses to profits. ADMA lost $0.34 per share in 2022 and $0.12 in 2023, then earned $0.53 in 2024 and $0.66 in 2025, up 24.5%. Annual revenue rose from $154.1 million in 2022 to $510.2 million in 2025, about 3.3 times. Q4 2025 set the table highs at $0.21 per share and $139.2 million in revenue. Revenue then dipped to $114.5 million in Q1 2026 before recovering in Q2. First-half 2026 EPS was $0.33, against $0.29 a year earlier. ADMA beat EPS estimates in 14 of the 20 quarters, and in three of the last four.

Third-quarter results came between November 5 and November 10 in each year shown, most recently on November 5, 2025. That points to early November 2026 for Q3. The report will show how revenue compares with the $134.2 million of Q3 2025.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | $0.16 | $0.16 | 0.98% | $125.3M | $124.4M |
| Q1 2026 | May 6, 2026 | $0.19 | $0.17 | -11.74% | $140.0M | $114.5M |
| Q4 2025 | Feb 25, 2026 | $0.19 | $0.21 | 15.24% | $139.6M | $139.2M |
| Q3 2025 | Nov 5, 2025 | $0.15 | $0.16 | 9.43% | $131.9M | $134.2M |
| Q2 2025 | Aug 6, 2025 | $0.14 | $0.15 | 7.75% | $121.8M | $122.0M |
| Q1 2025 | May 7, 2025 | $0.15 | $0.14 | -11.22% | $116.4M | $114.8M |
| Q4 2024 | Mar 3, 2025 | $0.15 | $0.14 | -6.07% | $112.8M | $117.5M |
| Q3 2024 | Nov 7, 2024 | $0.13 | $0.16 | 25.38% | $105.8M | $119.8M |
| Q2 2024 | Aug 8, 2024 | $0.08 | $0.14 | 77.25% | $86.4M | $107.2M |
| Q1 2024 | May 9, 2024 | $0.06 | $0.09 | 62.00% | $77.3M | $81.9M |
| Q4 2023 | Feb 28, 2024 | $0.03 | −$0.08 | -420.00% | $72.1M | $73.9M |
| Q3 2023 | Nov 8, 2023 | −$0.01 | $0.01 | 233.33% | $62.1M | $67.3M |
| Q2 2023 | Aug 9, 2023 | −$0.03 | −$0.02 | 29.60% | $55.5M | $60.1M |
| Q1 2023 | May 10, 2023 | −$0.04 | −$0.03 | 29.41% | $51.3M | $56.9M |
| Q4 2022 | Mar 23, 2023 | −$0.07 | −$0.06 | 14.29% | $46.4M | $50.0M |
| Q3 2022 | Nov 9, 2022 | −$0.08 | −$0.08 | -3.23% | $34.5M | $41.1M |
| Q2 2022 | Aug 10, 2022 | −$0.08 | −$0.07 | 12.50% | $31.8M | $33.9M |
| Q1 2022 | May 11, 2022 | −$0.09 | −$0.13 | -52.94% | $25.9M | $29.1M |
| Q4 2021 | Mar 24, 2022 | −$0.09 | −$0.09 | 2.91% | $21.8M | $26.4M |
| Q3 2021 | Nov 10, 2021 | −$0.14 | −$0.13 | 6.00% | $18.7M | $20.7M |

## Frequently Asked Questions

### When did ADMA Biologics (ADMA) last report earnings?

ADMA Biologics last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did ADMA beat earnings estimates?

Yes. ADMA Biologics reported EPS of $0.16 for Q2 2026 against a $0.16 estimate — a 0.98% beat.

### How much revenue did ADMA report last quarter?

ADMA Biologics reported $124.4M in revenue for Q2 2026, against a consensus estimate of $125.3M.

## Similar Stocks

- [ALLO](https://www.lighthorse.io/tickers/allo) — Allogene Therapeutics, Inc. - Common Stock
- [ACAD](https://www.lighthorse.io/tickers/acad) — ACADIA Pharmaceuticals Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).